Takeda Pharmaceutical Co Ltd
takeda.comWhat Do They Do?
Develops and sells prescription medicines, plasma-derived therapies and vaccines for patients worldwide.
20-F for FY2026, filed Jun 17, 2026
Who Are Their Customers?
Takeda sells products to wholesalers, while some indirect customers buy through wholesalers at contract prices. Its customer relationships also include purchasing organizations, health insurers and managed healthcare organizations.
20-F for FY2026, filed Jun 17, 2026Customer rebates: Customer rebates including commercial managed care in the U.S. are offered to purchasing organizations, health insurance…View ↗
How Are They Changing?
Vaccines in the commercial focus
The older report lists gastrointestinal, rare diseases, plasma-derived therapies, oncology and neuroscience as key commercial areas; the latest adds vaccines to its key business areas.
20-F for FY2023, filed Jun 28, 2023 20-F for FY2026, filed Jun 17, 2026Our commercial efforts are focused on five key business areas of GI, Rare Diseases, PDT, Oncology, and Neuroscience, which in the fiscal…View ↗
Our commercial efforts are focused on six key business areas of GI, Rare Diseases, PDT, Oncology, Vaccines and Neuroscience, which in the…View ↗
R&D therapeutic focus
The older report places rare genetics and hematology among its core R&D areas; the latest centers core R&D on gastrointestinal and inflammation, neuroscience, and oncology, with targeted investment in plasma-derived therapies.
20-F for FY2023, filed Jun 28, 2023 20-F for FY2026, filed Jun 17, 2026Takeda is a global, values-based, R&D-driven biopharmaceutical company with a diverse portfolio, engaged primarily in the research…View ↗
Our R&D engine is focused on translating science into highly innovative, life-transforming medicines that make a critical difference to…View ↗
Who Do They Compete With?
Competes with Eli Lilly and, Amgen, Pfizer, Organon, Celltrion, UCB, Biogen, Johnson & Johnson, Dr. Falk Pharma, Sanofi, Sobi, Merck, Amicus, Chiesi, Pharming, BioCryst, Ionis, Argenx, Taiho Pharmaceutical, and GSK
20-F for FY2026, filed Jun 17, 2026Eli Lilly and CompanyView ↗
Loading...
